Literature DB >> 11154231

Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

O Hjertner1, H Hjorth-Hansen, M Börset, C Seidel, A Waage, A Sundan.   

Abstract

Bone morphogenetic proteins (BMPs) can be isolated from organic bone matrix and are able to initiate de novo cartilage and bone formation. Here it is shown that BMP-4 inhibited DNA synthesis in a dose-dependent manner in 3 IL-6-dependent multiple myeloma (MM) cell lines (OH-2, IH-1, and ANBL-6). In contrast, no effect on DNA synthesis was observed in 3 IL-6-independent MM cell lines (JJN-3, U266, and RPMI 8226). BMP-4 induced cell cycle growth arrest in the G(0)/G(1) phase in OH-2 and ANBL-6 cells but not in IH-1 cells. BMP-4 induced apoptosis in OH-2 and IH-1 cells, but not significantly in ANBL-6 cells. Furthermore, BMP-4 induced apoptosis in freshly isolated MM cells from 4 of 13 patients. In the OH-2 and ANBL-6 cell lines and in a patient sample, immunoblotting showed that BMP-4 down-regulated IL-6-induced tyrosine phosphorylation of Stat3, suggesting a mechanism for the apparent antagonism between IL-6 and BMP-4. BMP-4 or analogues may be attractive therapeutic agents in MM because of possible beneficial effects on both tumor burden and bone disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154231     DOI: 10.1182/blood.v97.2.516

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

2.  Role of decorin in the antimyeloma effects of osteoblasts.

Authors:  Xin Li; Angela Pennisi; Shmuel Yaccoby
Journal:  Blood       Date:  2008-04-24       Impact factor: 22.113

3.  Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion.

Authors:  Trevor G Shepherd; Michelle L Mujoomdar; Mark W Nachtigal
Journal:  J Ovarian Res       Date:  2010-02-26       Impact factor: 4.234

4.  A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression.

Authors:  Sabino Ciavarella; Anna Caselli; Antonella Valentina Tamma; Annalisa Savonarola; Giuseppe Loverro; Roberto Paganelli; Marco Tucci; Franco Silvestris
Journal:  Stem Cells Dev       Date:  2015-03-11       Impact factor: 3.272

5.  Global methylation profiling of lung cancer identifies novel methylated genes.

Authors:  Z Dai; R R Lakshmanan; W G Zhu; D J Smiraglia; L J Rush; M C Frühwald; R M Brena; B Li; F A Wright; P Ross; G A Otterson; C Plass
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

6.  Expression of bone morphogenic protein-4 is inversely related to prevalence of lymph node metastasis in gastric adenocarcinoma.

Authors:  Seong-Gon Kim; Hye-Rim Park; Soo-Kee Min; Je-Yong Choi; Sung-Hoon Koh; Jong-Wan Kim; Hae-Wan Lee
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

Review 7.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

8.  Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma cells.

Authors:  Maike Haubold; Andreas Weise; Harald Stephan; Nicole Dünker
Journal:  Int J Biol Sci       Date:  2010-11-24       Impact factor: 6.580

9.  Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

Authors:  Shmuel Yaccoby; Michele J Wezeman; Maurizio Zangari; Ronald Walker; Michele Cottler-Fox; Danna Gaddy; Wen Ling; Rinku Saha; Bart Barlogie; Guido Tricot; Joshua Epstein
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

Review 10.  Bone metastasis: the importance of the neighbourhood.

Authors:  Peter I Croucher; Michelle M McDonald; T John Martin
Journal:  Nat Rev Cancer       Date:  2016-05-25       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.